FDA Rejects NeuroPace's RNS Indication Expansion for Generalized Epilepsy
NPCE sits 78% above its 52-week low of $7.563.
Summary
The FDA has informed NeuroPace that its PMA supplement to expand the RNS System label into drug-resistant idiopathic generalized epilepsy (IGE) is not approvable in its current form. The company met with the agency and plans to submit a Submission Issue Request (SIR) and amend the filing with additional data, including further context on patient populations from the NAUTILUS trial. While management expressed encouragement from subsequent FDA discussions, the initial rejection is a setback for a key growth catalyst. The NAUTILUS study showed strong efficacy—77% median reduction in GTC seizures at 18 months and 100% median reduction at 24 months for patients with long-term stimulation—but the FDA requires more information. This follows strong Q1 results and raised guidance, but the regulatory delay could push out the timeline for entering a market with no approved neuromodulation options. Investors will watch for updates from the SIR meeting and any revised approval timeline.
At the time of this announcement, NPCE was trading at $13.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $522M. The 52-week trading range was $7.56 to $19.60. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.